Vaccination of carp against SVCV with an oral DNA vaccine or an insect cells-based subunit vaccine
Language English Country England, Great Britain Media print-electronic
Document type Journal Article
PubMed
29567136
DOI
10.1016/j.fsi.2018.03.028
PII: S1050-4648(18)30145-1
Knihovny.cz E-resources
- Keywords
- Alginate encapsulation, Baculovirus, DNA vaccine, Insect cells, SVCV glycoprotein,
- MeSH
- Vaccines, DNA administration & dosage classification pharmacology MeSH
- Rhabdoviridae Infections immunology prevention & control veterinary virology MeSH
- Carps * MeSH
- Fish Diseases immunology prevention & control virology MeSH
- Rhabdoviridae immunology MeSH
- Sf9 Cells MeSH
- Spodoptera MeSH
- Vaccines, Subunit administration & dosage classification pharmacology MeSH
- Vaccination veterinary MeSH
- Viral Vaccines administration & dosage classification pharmacology MeSH
- Animals MeSH
- Check Tag
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Vaccines, DNA MeSH
- Vaccines, Subunit MeSH
- Viral Vaccines MeSH
We recently reported on a successful vaccine for carp against SVCV based on the intramuscular injection of a DNA plasmid encoding the SVCV glycoprotein (SVCV-G). This shows that the intramuscular (i.m.) route of vaccination is suitable to trigger protective responses against SVCV, and that the SVCV G-protein is a suitable vaccine antigen. Yet, despite the general success of DNA vaccines, especially against fish rhabdoviruses, their practical implementation still faces legislative as well as consumer's acceptance concerns. Furthermore, the i.m. route of plasmid administration is not easily combined with most of the current vaccination regimes largely based on intraperitoneal or immersion vaccination. For this reason, in the current study we evaluated possible alternatives to a DNA-based i.m. injectable vaccine using the SVCV-G protein as the vaccine antigen. To this end, we tested two parallel approaches: the first based on the optimization of an alginate encapsulation method for oral delivery of DNA and protein antigens; the second based on the baculovirus recombinant expression of transmembrane SVCV-G protein in insect cells, administered as whole-cell subunit vaccine through the oral and injection route. In addition, in the case of the oral DNA vaccine, we also investigated the potential benefits of the mucosal adjuvants Escherichia coli lymphotoxin subunit B (LTB). Despite the use of various vaccine types, doses, regimes, and administration routes, no protection was observed, contrary to the full protection obtained with our reference i.m. DNA vaccine. The limited protection observed under the various conditions used in this study, the nature of the host, of the pathogen, the type of vaccine and encapsulation method, will therefore be discussed in details to provide an outlook for future vaccination strategies against SVCV.
Cell Biology and Immunology Group Wageningen University The Netherlands
INRA Infectiologie Expérimentale Rongeurs Poissons Université Paris Saclay Jouy en Josas France
INRA Virologie et Immunologie Moléculaires Université Paris Saclay Jouy en Josas France
Laboratory of Virology Wageningen University The Netherlands
References provided by Crossref.org